Combination of Haloperidol With UNC9994, β-arrestin-Biased Analog of Aripiprazole, Ameliorates Schizophrenia-Related Phenotypes Induced by NMDAR Deficit in Mice
The dual administration of haloperidol with UNC9994 at low doses represents a promising approach to ameliorate symptoms of schizophrenia. The combined drug regimen elicits synergistic effects specifically on pAkt-S473, suggesting it as a potential biomarker for antipsychotic actions.
Authors
- Marc G. Caron (ORCID: https://orcid.org/0000-0003-0172-2710)
- Ali Salahpour (ORCID: https://orcid.org/0000-0003-4712-2091)
- William C. Wetsel (ORCID: https://orcid.org/0000-0002-3592-7397)
- Tatiana V. Lipina (ORCID: https://orcid.org/0000-0003-1823-465X)
- Amy J. Ramsey (ORCID: https://orcid.org/0000-0002-2717-5279)
- Jean‐Martin Beaulieu (ORCID: https://orcid.org/0000-0002-0446-7447)
- Jonathan S. Thacker (ORCID: https://orcid.org/0000-0002-3858-2718)
- Huy Giang
Institutions
- Mount Sinai Hospital (CA)
- Duke University (US)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Duke Medical Center (US)
- Duke University Hospital (US)
Publication Details
- Journal
- The International Journal of Neuropsychopharmacology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1093/ijnp/pyae060
- Citations
- 1
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Canadian Institutes of Health Research